The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | An overview of current treatment guidelines for appendix cancer
John Paul Shen, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the treatment of appendix cancer, noting that due to its rarity, high-quality clinical trial data is limited, and thus the effectiveness of chemotherapy after surgery for early-stage patients was unclear. Research has shown patients with stage two or three appendix cancer tend to do well with surgery alone, leading to a shift away from recommending chemotherapy after surgery for these patients. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
